OCD-Related Disorders

A sertraline dose that would count as an adequate depression trial left his obsessions and compulsions essentially untouched — because OCD's own dose-response curve runs well past that ceiling.

Clomipramine's own meta-analytic numbers edge out the SSRIs for OCD specifically — the disagreement is whether that edge is worth its cardiac and anticholinergic price for a first medication trial.

Two adequate SSRI trials have failed him, and the three real next-step options — antipsychotic augmentation, adding clomipramine, or switching class again — have no guideline-ranked order to choose between.

Six weeks of fluoxetine and no clear improvement looked like a failed trial to the covering resident — but OCD's own antiobsessional response window runs nearly twice that long.

Five adequate medication trials and three years out of work later, the real question isn't whether deep brain stimulation works — it's whether pharmacotherapy is actually exhausted enough to justify neurosurgery.

She has heard ketamine works fast for depression and wants to know why it isn't being offered for her OCD — the honest answer is that its OCD evidence is real but far thinner, and the benefit fades in days rather than weeks.

Both teenagers carry the identical FDA black-box warning on the identical drug class — but the OCD patient's own diagnosis requires reaching a meaningfully higher dose to get there, sharpening a risk conversation the depression patient's case leaves comparatively familiar.

OCD's own high-dose SSRI philosophy is well established — the real question here is whether body dysmorphic disorder, a related but genuinely distinct diagnosis, actually needs the same ceiling or an even higher one.

A plastic surgeon paused a rhinoplasty consultation over a feeling that something didn't add up — the real stakes of telling BDD apart from an ordinary cosmetic concern before, not after, an elective procedure.

Hoarding disorder shares OCD's DSM-5 chapter, but its own SSRI trials show a genuinely weaker and less consistent response — raising a real question about whether medication is worth trying at all, and for how long.

SSRIs have a genuinely disappointing track record in trichotillomania — N-acetylcysteine offers a distinct glutamate-based mechanism with real but mixed trial support, not a settled answer.

Excoriation disorder shares OCD's DSM-5 chapter and its first-line drug class, but not, it turns out, anything close to OCD's SSRI response rate — a genuine gap between shared classification and shared pharmacology.

Antipsychotic augmentation already failed her — memantine's distinct glutamatergic mechanism has real trial support in treatment-resistant OCD, but sits far behind antipsychotic augmentation in how often it's actually reached for.

He read about psilocybin's Phase 3 depression trials and wants to know when the same option might reach his OCD — the honest answer is that OCD's psilocybin research sits at a genuinely much earlier, thinner stage.